Table 4.
Relation between serum CA19-9 and CEA levels and clinicopathologic features of tumors in 35 patients with cholangiocarcinoma (mean ± SD)
| No. of | CA19-9 | CEA | |
| patients | (KU/L) | (μg/L) | |
| Well-differentiated | 16 | 261.67 ± 6.31 | 34.37 ± 11.29 |
| adenocarcinoma | |||
| Moderately-differentiated | 12 | 270.56 ± 4.57 | 38.42 ± 19.23 |
| adenocarcinoma | |||
| Poorly-differentiated | 5 | 302.71 ± 5.81 | 48.23 ± 23.64 |
| adenocarcinoma | |||
| Anaplastic carcinoma | 1 | 468 | 64 |
| Adenosquamous carcinoma | 1 | 293 | 27 |
| Perineural infiltration | |||
| Positive | 23 | 310.12 ± 7.11a | 37.64 ± 10.35b |
| Negative | 10 | 195.16 ± 6.48 | 21.28 ± 13.15 |
| Venous invasion | |||
| Positive | 17 | 318.49 ± 3.27b | 39.78 ± 18.41b |
| Negative | 18 | 253.08 ± 5.37 | 29.67 ± 20.13 |
| Lymph node metastasis | |||
| Positive | 18 | 345.66 ± 4.23a | 46.37 ± 9.46b |
| Negative | 17 | 265.30 ± 4.58 | 31.89 ± 16.46 |
a
P < 0.01, bP < 0.05, cP < 0.05 vs negative group.